Antidepressants and cardiovascular adverse events: A narrative review

Mohammad Hassan Nezafati, Mohammad Vojdanparast, Pouya Nezafati, Mohammad Hassan Nezafati, Mohammad Vojdanparast, Pouya Nezafati

Abstract

Background: Major depression or deterioration of previous mood disorders is a common adverse consequence of coronary heart disease, heart failure, and cardiac revascularization procedures. Therefore, treatment of depression is expected to result in improvement of mood condition in these patients. Despite demonstrated effects of anti-depressive treatment in heart disease patients, the use of some antidepressants have shown to be associated with some adverse cardiac and non-cardiac events. In this narrative review, the authors aimed to first assess the findings of published studies on beneficial and also harmful effects of different types of antidepressants used in patients with heart diseases. Finally, a new categorization for selecting antidepressants according to their cardiovascular effects was described.

Methods: Using PubMed, Web of Science, SCOPUS, Index Copernicus, CINAHL, and Cochrane Database, we identified studies designed to evaluate the effects of depression and also using antidepressants on cardiovascular outcome. A 40 studies were finally assessed systematically. Among those eligible studies, 14 were cohort or historical cohort studies, 15 were randomized clinical trial, 4 were retrospective were case-control studies, 3 were meta-analyses and 2 animal studies, and 2 case studies.

Results: According to the current review, we recommend to divide antidepressants into three categories based on the severity of cardiovascular adverse consequences including (1) the safest drugs including those drugs with cardio-protective effects on ventricular function, as well as cardiac conductive system including selective serotonin reuptake inhibitors, (2) neutralized drugs with no evidenced effects on cardiovascular system including serotonin-norepinephrine reuptake inhibitors, and (3) harmful drugs with adverse effects on cardiac function, hemodynamic stability, and heart rate variability including tricyclic antidepressants, serotonin antagonist and reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants.

Conclusion: The presented categorization of antidepressants can be clinically helpful to have the best selection for antidepressants to minimizing their cardiovascular harmful effects.

Keywords: Antidepressants; Review; Selective Serotonin Reuptake Inhibitors; Tricyclic Antidepressant.

Figures

Figure 1
Figure 1
Process for selecting final studies

References

    1. Fan H, Yu W, Zhang Q, Cao H, Li J, Wang J, et al. Depression after heart failure and risk of cardiovascular and all-cause mortality: a meta-analysis. Prev Med. 2014;63:36–42.
    1. Tully PJ. Psychological depression and cardiac surgery: a comprehensive review. J Extra Corpor Technol. 2012;44(4):224–32.
    1. Mavrides N, Nemeroff C. Treatment of depression in cardiovascular disease. Depress Anxiety. 2013;30(4):328–41.
    1. Ramamurthy G, Trejo E, Faraone SV. Depression treatment in patients with coronary artery disease: a systematic review. Prim Care Companion CNS Disord. 2013;15(5)
    1. Nezafati MH, Nezafati P, Amoueian S, Attaranzadeh A, Rahimi HR. Immunohistochemistry comparing endoscopic vein harvesting vs. open vein harvesting on saphenous vein endothelium. J Cardiothorac Surg. 2014;9:101.
    1. Lange-Asschenfeldt C, Lederbogen F. Antidepressant therapy in coronary artery disease. Nervenarzt. 2011;82(5):657–64.
    1. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2011;(9):CD008012.
    1. Shanmugasegaram S, Russell KL, Kovacs AH, Stewart DE, Grace SL. Gender and sex differences in prevalence of major depression in coronary artery disease patients: a meta-analysis. Maturitas. 2012;73(4):305–11.
    1. Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768–75.
    1. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527–37.
    1. Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23(11):1391–400.
    1. Hanash JA, Hansen BH, Hansen JF, Nielsen OW, Rasmussen A, Birket-Smith M. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. J Cardiovasc Pharmacol. 2012;60(4):397–405.
    1. Santangelo A, Testai M, Barbagallo P, Crisafulli C, Grasso S, Manuele S, et al. Use of specific serotonin reuptake inhibitors (SSRIs) (Sertraline or Citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly: evidence from a Sicilian population > 80 years recovered in the assisted sanitary residences (RSA). Arch Gerontol Geriatr. 2009;48(3):350–2.
    1. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701–9.
    1. Wilens TE, Biederman J, March JS, Wolkow R, Fine CS, Millstein RB, et al. Absence of cardiovascular adverse effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38(5):573–7.
    1. Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, et al. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther. 2012;92(1):72–9.
    1. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 1998;155(5):660–5.
    1. Yeragani VK, Pesce V, Jayaraman A, Roose S. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry. 2002;52(5):418–29.
    1. Acharya T, Acharya S, Tringali S, Huang J. Association of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population. Pharmacotherapy. 2013;33(10):1053–61.
    1. Pequignot R, Tzourio C, Peres K, Ancellin ML, Perier MC, Ducimetiere P, et al. Depressive symptoms, antidepressants and disability and future coronary heart disease and stroke events in older adults: the Three City Study. Eur J Epidemiol. 2013;28(3):249–56.
    1. Zuidersma M, Conradi HJ, van Melle JP, Ormel J, de Jonge P. Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J Psychosom Res. 2013;74(1):25–30.
    1. Jerrell JM, McIntyre RS. Cardiovascular and neurological adverse events associated with antidepressant treatment in children and adolescents. J Child Neurol. 2009;24(3):297–304.
    1. Grace SL, Leung YW, Stewart DE. A prospective examination of antidepressant use and its correlates in patients with acute coronary syndrome. Psychosomatics. 2008;49(3):199–207.
    1. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry. 2006;51(14):923–9.
    1. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792–8.
    1. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279(4):287–91.
    1. Jeon SH, Jaekal J, Lee SH, Choi BH, Kim KS, Jeong HS, et al. Effects of nortriptyline on QT prolongation: a safety pharmacology study. Hum Exp Toxicol. 2011;30(10):1649–56.
    1. Bar KJ, Schuhmacher A, Hofels S, Schulz S, Voss A, Yeragani VK, et al. Reduced cardio-respiratory coupling after treatment with nortriptyline in contrast to S-citalopram. J Affect Disord. 2010;127(1-3):266–73.
    1. Kiev A, Masco HL, Wenger TL, Johnston JA, Batey SR, Holloman LC. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry. 1994;6(2):107–15.
    1. Thayssen P, Bjerre M, Kragh-Sorensen P, Moller M, Petersen OL, Kristensen CB, et al. Cardiovascular effect of imipramine and nortriptyline in elderly patients. Psychopharmacology (Berl) 1981;74(4):360–4.
    1. Giardina EG, Johnson LL, Vita J, Bigger JT, Brem RF. Effect of imipramine and nortriptyline on left ventricular function and blood pressure in patients treated for arrhythmias. Am Heart J. 1985;109(5 Pt 1):992–8.
    1. Hamer M, Batty GD, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J. 2011;32(4):437–42.
    1. Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Keefover R. Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients. J Clin Psychiatry. 1982;43(5 Pt 2):8–15.
    1. Waslick BD, Walsh BT, Greenhill LL, Giardina EG, Sloan RP, Bigger JT, et al. Cardiovascular effects of desipramine in children and adults during exercise testing. J Am Acad Child Adolesc Psychiatry. 1999;38(2):179–86.
    1. Ho JM, Gomes T, Straus SE, Austin PC, Mamdani M, Juurlink DN. Adverse cardiac events in older patients receiving venlafaxine: a population-based study. J Clin Psychiatry. 2014;75(6):e552–e558.
    1. Xue F, Strombom I, Turnbull B, Zhu S, Seeger J. Treatment with duloxetine in adults and the incidence of cardiovascular events. J Clin Psychopharmacol. 2012;32(1):23–30.
    1. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30(5):437–55.
    1. Scheen AJ. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs. 2010;10(5):321–34.
    1. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–17.
    1. Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. Drug Saf. 2010;33(7):605–13.
    1. Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, et al. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. J Cardiovasc Pharmacol. 2008;52(5):393–402.
    1. Gaciong Z, Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. J Hum Hypertens. 2005;19(9):737–43.
    1. Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila) 2008;46(1):71–3.
    1. Krahn LE, Hanson CA, Pileggi TS, Rummans TA. Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia. J Clin Psychiatry. 2001;62(2):108–10.
    1. Boschmans SA, Perkin MF, Terblanche SE, Opie LH. The effects of imipramine, mianserin and trazodone on the chronotropic, inotropic and coronary vascular responses in the isolated perfused rat heart. Gen Pharmacol. 1989;20(2):233–7.
    1. Tulen JH, Bruijn JA, de Man KJ, Pepplinkhuizen L, van den Meiracker AH, Man in 't Veld AJ. Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770). J Clin Psychopharmacol. 1996;16(2):135–45.
    1. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010;67(11):1067–74.
    1. Rajpurohit N, Aryal SR, Khan MA, Stys AT, Stys TP. Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction. S D Med. 2014;67(4):137–9.
    1. Terhardt J, Lederbogen F, Feuerhack A, Hamann-Weber B, Gilles M, Schilling C, et al. Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. Clin Neuropharmacol. 2013;36(6):198–202.
    1. Giardina EG, Barnard T, Johnson L, Saroff AL, Bigger JT, Louie M. The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations. J Am Coll Cardiol. 1986;7(6):1363–9.
    1. Giardina EG, Cooper TB, Suckow R, Saroff AL. Cardiovascular effects of doxepin in cardiac patients with ventricular arrhythmias. Clin Pharmacol Ther. 1987;42(1):20–7.
    1. Jo SH, Youm JB, Lee CO, Earm YE, Ho WK. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol. 2000;129(7):1474–80.
    1. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol. 1999;128(2):479–85.
    1. Cohn JB, Wilcox CS, Goodman LI. Antidepressant efficacy and cardiac safety of trimipramine in patients with mild heart disease. Clin Ther. 1993;15(1):114–26.
    1. Himmelhoch JM, Schechtman K, Auchenbach R. The role of trazodone in the treatment of depressed cardiac patients. Psychopathology. 1984;17(Suppl 2):51–63.
    1. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry. 1997;42(4):290–5.
    1. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry. 1996;153(10):1313–7.
    1. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20(2):137–40.
    1. Nair GV, Gurbel PA, O'Connor CM, Gattis WA, Murugesan SR, Serebruany VL. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am J Cardiol. 1999;84(3):321–3.
    1. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996;94(12):3123–9.
    1. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med. 1997;102(1):54–9.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel